Clinical Study
Rozanolixizumab: A Study Drug for People with Myelin Oligodendrocyte Glycoprotein (MOG) antibody associated disease (MOG-AD)
Myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD) may inflame a persons central nervous system severely affecting nerves in the eyes, brain, and spinal cord. Rozanolixizumab is a study drug to help people with MOG-AD. Research is needed to learn the safety and effectiveness of the study drug. The information we gain may aid future patients.
For more information contact:
Ka-Ho Wong
ka-ho.wong@hsc.utah.edu
8015857575
IRB#: IRB_00148171
| PI: Stacey Clardy
| Department: NEUROLOGY
| Approval Date: 2022-10-05 06:00:00
Study Categories: Neurological Studies, Ophthalmic Studies
| Specialties: Neurology, Ophthalmology
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes